Characteristics | Patients treated with TGC before ASP (P1) (%) (N = 153) | Patients treated with TGC after ASP (P2) (%) (N = 116) | P |
---|---|---|---|
Age (years) (median; IQR) | 68 (47–80) | 70 (53–77) | 0.314 |
 ≤ 65 | 72 (47.1%) | 50 (43.1%) | 0.519 |
 > 65 | 81 (52.9%) | 66 (56.9%) | |
Gender | |||
 Male | 79 (51.6%) | 64 (55.2%) | 0.565 |
 Female | 74 (48.4%) | 52 (44.8%) | |
Comorbidities | |||
 Cardiovascular disease | 90 (58.8%) | 83 (71.6%) | 0.031 |
 Diabetes | 46 (30.1%) | 48 (41.4%) | 0.054 |
 Respiratory disease | 21 (13.7%) | 19 (16.4%) | 0.097 |
 Acute renal failure | 35 (22.9%) | 10 (8.6%) | 0.002 |
 chronic kidney disease | 19 (12.4%) | 23 (19.8%) | 0.097 |
 Chronic hepatic disease | 6 (3.9%) | 2 (1.7%) | 0.472 |
 Neutropenia (ANC < 500 cells/µL) | 30 (19.6%) | 0 | < 0.0001 |
 Malignancy | 50 (32.7%) | 22 (19.0%) | 0.012 |
  Leukemia | 24 (15.7%) | 2 (1.7%) | < 0.0001 |
  Lymphoma | 11 (7.2%) | 1 (0.9%) | 0.013 |
  Solid tumor | 15 (9.8%) | 19 (16.4%) | 0.108 |
 Bone marrow transplantation | 14 (9.2%) | 2 (1.7%) | 0.011 |
  Autologous | 4 (2.6%) | 1 (0.9%) | 0.394 |
  Allogeneic | 10 (6.5%) | 1 (0.9%) | 0.026 |
Use of vasopressors before TGC use by 24Â h | 37 (24.2%) | 15 (12.9%) | 0.021 |
Mechanical ventilation | 35 (22.9%) | 13 (11.2%) | 0.013 |
Indications for TGC therapy | |||
 FDA approved | 29 (19%) | 91 (78.4%) | < 0.0001 |
 Off-label | 124 (81%) | 25 (21.6%) |  |
FDA-approved indications | |||
 cSSTI | 18 (11.8%) | 56 (48.3%) | < 0.0001 |
 cIAI | 4 (2.6%) | 33 (28.3%) | < 0.0001 |
 CAP | 7 (4.6%) | 2 (1.7%) | 0.082 |
Off-label indications | |||
 HAP | 30 (19.6%) | 6 (5.2%) | 0.001 |
 VAP | 40 (26.1%) | 4 (3.4%) | < 0.0001 |
 BSI | 14 (9.2%) | 0 | 0.001 |
 Sepsis | 14 (9.2%) | 3 (2.6%) | 0.028 |
 UTI | 6 (3.9%) | 2 (1.7%) | 0.472 |
 FN | 24 (15.7%) | 1 (0.9%) | < 0.0001 |
 Diabetic ulcer | 8 (5.2%) | 8 (6.9%) | 0.567 |
Duration of TGC therapy regardless the indication (days) (median/IQR) | 8 (5–13) | 7 (5–9) | 0.973 |
 ≤ 7 days | 67 (43.8%) | 64 (55.2%) | 0.064 |
 > 10 days | 55 (35.9%) | 21 (18.1%) | 0.001 |
 > 15 days | 27 (17.6%) | 7 (6%) | 0.005 |
Duration of TGC therapy in cIAI (days) (median/IQR) | 10 (7–12) | 7 (4–8) | 0.137 |
 > 5 daysa | 3/4 (75%) | 22/33 (66.7%) | 0.9 |
Duration of TGC therapy in cSSTI (days) (median/IQR) | 8 (5–11) | 7 (5–10) | 0.499 |
 > 7 daysb | 10/18 (55.6%) | 26/56 (46.4%) | 0.5 |
 > 10 daysb | 5/18 (27.8%) | 12/56 (21.4%) | 0.75 |
Treatment strategy of TGC | |||
 Empiric | 67 (43.8%) | 63 (54.3%) | 0.087 |
 Targeted | 86 (56.2%) | 53 (45.7%) | |
 Monotherapy | 26 (17%) | 47 (40.5%) | < 0.0001 |
 Combination therapyc | 127 (83%) | 69 (59.5%) |